Evidence map›Paper›PMID 34718033›Full record

SynthesisCurrent problems in cardiology2022

Comparison of Coronary Artery Involvement and Mortality in STEMI Patients With and Without SARS-CoV-2 During the COVID-19 Pandemic: A Systematic Review and Meta-Analysis.

Ravi A Thakker, Ayman Elbadawi, Khaled F Chatila, Sachin S Goel, David Reynoso, Rafic F Berbarie, Syed Gilani, Umamahesh Rangasetty, Wissam Khalife

Open access · greenAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Current problems in cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Ravi A ThakkerDepartment of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA. Electronic address: ravi.a.thakker@gmail.com.
Ayman ElbadawiDivision of Cardiology, Baylor College of Medicine, Houston, TX, USA.
Khaled F ChatilaDivision of Cardiology, University of Texas Medical Branch, Galveston, TX, USA.
Sachin S GoelDepartment of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, TX, USA.
David ReynosoDivision of Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA.
Rafic F BerbarieDivision of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Syed GilaniDivision of Cardiology, University of Texas Medical Branch, Galveston, TX, USA.
Umamahesh RangasettyDivision of Cardiology, University of Texas Medical Branch, Galveston, TX, USA.
Wissam KhalifeDivision of Cardiology, University of Texas Medical Branch, Galveston, TX, USA.
The University of Texas Medical Branch at Galveston · USBaylor College of Medicine · USHouston Methodist · USThe University of Texas Southwestern Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCardiovascular injury with SARS-CoV-2 infection is well known. Several studies have outlined baseline characteristics in patients presenting with STEMI and SARS-CoV-2. Paucity in data exists in selective coronary involvement in patients with STEMI and SARS-CoV-2 during the COVID-19 pandemic.

methodsA systematic search and meta-analysis of studies meeting the inclusion and exclusion criteria obtained from MEDLINE, Scopus, and Cochrane databases was performed utilizing PRISMA criteria. The main outcome was likelihood of coronary artery involvement among patients with STEMI and SARS-CoV-2 versus without SARS-CoV-2. The primary adverse outcome measured was in-hospital mortality.

resultsThe final analysis included 5 observational studies with a total of 2,266 patients. There was no statistical significance in LM (OR 1.40; 95% CI: 0.68, 2.90), LAD (OR 1.09; 95% CI 0.83, 1.43), LCX (OR 1.17; 95% CI: 0.75, 1.85), or RCA (OR 0.59; 95% CI: 0.30, 1.17) disease among the 2 groups. LAD disease was the most prevalent coronary involvement among patients with STEMI and SARS-CoV-2 (49.6%). Higher in-hospital mortality was observed in the STEMI and SARS-CoV-2 group (OR 5.24; 95% CI: 3.63, 7.56).

conclusionsOur analysis demonstrated no statistical significance in selective coronary involvement in patients with STEMI and SARS-CoV-2 during the COVID-19 pandemic. The higher mortality among patients with SARS-CoV-2 and STEMI has been noted in prior studies with concerns being late presentation due to fear of infection, delayed care time, and poor resource allocation. Focus should be placed on identifying and managing comorbidities to reduce mortality.

Indexed as

COVID-19Percutaneous Coronary InterventionST Elevation Myocardial InfarctionCoronary VesselsHumansPandemicsSARS-CoV-2(CAD), coronary artery disease(COVID-19), coronavirus disease 2019(LAD), left anterior descending(LCX), left circumflex(LM), left main(OR), odds ratio(PRISMA), Preferred Reporting Items for Systematic Reviews and Meta-Analyses(RCA), right coronary artery(SARS-CoV-2), severe acute respiratory syndrome coronavirus 2(STEMI), ST segment elevation myocardial infarction

Identifiers

PMID34718033
PMCPMC8552666
OpenAlexW3210634407

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.